RHJA
KRTX

Rice Hall James & Associates’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Rice Hall James & Associates’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50,171
Closed -$15.9M – 275
2023
Q4 		$15.9M Buy
50,171
+10,790
+27% +$2.1M 0.92% 31
2023
Q3 		$6.66M Buy
39,381
+21,465
+120% +$4.04M 0.42% 59
2023
Q2 		$3.89M Sell
17,916
-283
-2% -$60.6K 0.22% 109
2023
Q1 		$3.31M Buy
+18,199
New +$3.48M 0.19% 133

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Rice Hall James & Associates's KRTX Position: Q1 2024 in Review

Rice Hall James & Associates sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 50,171 shares — an estimated $15.9M sold.

Rice Hall James & Associates first reported a position in KRTX in Q1 2023 and held it in 4 quarters. The position peaked at $15.9M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Rice Hall James & Associates reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Rice Hall James & Associates sold 50,171 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $15.9M.
  • Rice Hall James & Associates first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2023 and held it in 4 quarters.
  • Rice Hall James & Associates's Karuna Therapeutics, Inc. Common Stock position peaked at $15.9M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Rice Hall James & Associates's 13F filing for Q1 2024, filed 23 Apr 2024.